HY-1272

Primary Objective: To assess the safety and tolerability of intravenous HY1272 in patients with locally advanced or metastatic epidermal growth factor receptor-sensitive mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). Secondary Objectives: 1) To determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of HY1272 monotherapy. 2) To evaluate the immunogenicity of HY1272 at steady state after a single and multiple doses. 3) To evaluate the pharmacokinetics of HY1272 after a single and multiple doses. 4) To preliminarily assess the antitumor efficacy of HY1272. Exploratory Objectives: 1) To explore the relationship between PK and selected endpoints (which may include biomarkers), where appropriate. 2) To collect and store diagnostic tumor samples and any fresh tumor biopsy samples for future exploratory studies that may be related to the development of NSCLC and/or the antitumor activity response of HY1272.